Center-Authored Papers

Filters: Author is Gilbert, Peter  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
2012
Janes H, Frahm N, DeCamp A, Rolland M, Gabriel E, Wolfson J, Hertz T, Kallas E, Goepfert P, Friedrich DP et al..  2012.  MRKAd5 HIV-1 Gag/Pol/Nef Vaccine-Induced T-Cell Responses Inadequately Predict Distance of Breakthrough HIV-1 Sequences to the Vaccine or Viral Load.. PloS one. 7(8):e43396. Abstract
Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, Casapia M, Santiago S, Gilbert P, Corey L et al..  2012.  Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study).. The Journal of infectious diseases. 206(2):258-266. Abstract
Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, McLinden R, Tovanabutra S, Laurence-Chenine A, Sanders-Buell E et al..  2012.  Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials.. The Journal of infectious diseases. 206(3):431-41. Abstract
Robb ML, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Kunasol P, Khamboonruang C, Thongcharoen P, Morgan P, Benenson M et al..  2012.  Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.. The Lancet infectious diseases. 12(7):531-7. Abstract
Rolland M, Gilbert P.  2012.  Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide.. AIDS research and human retroviruses. 28(4):400-4. Abstract
2013
Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, Casapia M, Santiago S, Huang Y, Gilbert P et al..  2013.  Reply to richie and villasante.. The Journal of infectious diseases. 207(4):690-2.
Janes H, Gilbert P, Buchbinder S, Kublin J, Sobieszczyk ME, Hammer SM.  2013.  In Pursuit of an HIV Vaccine: Designing Efficacy Trials in the Context of Partially Effective Non-Vaccine Prevention Modalities.. AIDS research and human retroviruses. Abstract
Fong Y, Sebestyen K, Yu X, Gilbert P, Self S.  2013.  nCal: an R package for non-linear calibration.. Bioinformatics (Oxford, England). Abstract
Gottardo R, Bailer RT, Korber BT, Gnanakaran S, Phillips J, Shen X, Tomaras GD, Turk E, Imholte G, Eckler L et al..  2013.  Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial.. PloS one. 8(9):e75665. Abstract
Liu P, Yates NL, Shen X, Bonsignori M, Moody AM, Liao H-X, Fong Y, Alam MS, Overman GR, Denny T et al..  2013.  Infectious Virion Capture by HIV-1 gp120 Specific IgG from RV144 Vaccinees.. Journal of virology. Abstract
Hertz T, Ahmed H, Friedrich DP, Casimiro DR, Self SG, Corey L, McElrath MJ, Buchbinder S, Horton H, Frahm N et al..  2013.  HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1.. PLoS pathogens. 9(6):e1003404. Abstract
259
Liu P, Yates NL, Shen X, Bonsignori M, Moody AM, Liao H-X, Fong Y, Alam MS, Overman GR, Denny T et al..  2013.  Infectious Virion Capture by HIV-1 gp120 Specific IgG from RV144 Vaccinees.. Journal of virology. Abstract
August 2013
Fong Y, Sebestyen K, Yu X, Gilbert P, Self S.  2013.  nCal: an R package for non-linear calibration.. Bioinformatics (Oxford, England). Abstract
Bioinformatics Core Facility
Lin L, Finak G, Ushey K, Seshadri C, Hawn TR, Frahm N, Scriba TJ, Mahomed H, Hanekom W, Bart P-A et al..  2015.  COMPASS identifies T-cell subsets correlated with clinical outcomes.. Nature biotechnology. 33(6):610-6. Abstract
Center-Authored Paper
Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, Casapia M, Santiago S, Gilbert P, Corey L et al..  2012.  Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study).. The Journal of infectious diseases. 206(2):258-266. Abstract
Clinical Research Division
Janes H, Frahm N, DeCamp A, Rolland M, Gabriel E, Wolfson J, Hertz T, Kallas E, Goepfert P, Friedrich DP et al..  2012.  MRKAd5 HIV-1 Gag/Pol/Nef Vaccine-Induced T-Cell Responses Inadequately Predict Distance of Breakthrough HIV-1 Sequences to the Vaccine or Viral Load.. PloS one. 7(8):e43396. Abstract
Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, Casapia M, Santiago S, Huang Y, Gilbert P et al..  2013.  Reply to richie and villasante.. The Journal of infectious diseases. 207(4):690-2.
Flow Cytometry Core Facility
Lin L, Finak G, Ushey K, Seshadri C, Hawn TR, Frahm N, Scriba TJ, Mahomed H, Hanekom W, Bart P-A et al..  2015.  COMPASS identifies T-cell subsets correlated with clinical outcomes.. Nature biotechnology. 33(6):610-6. Abstract
January 2013
Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, Casapia M, Santiago S, Huang Y, Gilbert P et al..  2013.  Reply to richie and villasante.. The Journal of infectious diseases. 207(4):690-2.
July 2013
Hertz T, Ahmed H, Friedrich DP, Casimiro DR, Self SG, Corey L, McElrath MJ, Buchbinder S, Horton H, Frahm N et al..  2013.  HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1.. PLoS pathogens. 9(6):e1003404. Abstract
June 2012
Robb ML, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Kunasol P, Khamboonruang C, Thongcharoen P, Morgan P, Benenson M et al..  2012.  Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.. The Lancet infectious diseases. 12(7):531-7. Abstract
Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, McLinden R, Tovanabutra S, Laurence-Chenine A, Sanders-Buell E et al..  2012.  Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials.. The Journal of infectious diseases. 206(3):431-41. Abstract
May 2012
Rolland M, Gilbert P.  2012.  Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide.. AIDS research and human retroviruses. 28(4):400-4. Abstract
Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, Casapia M, Santiago S, Gilbert P, Corey L et al..  2012.  Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study).. The Journal of infectious diseases. 206(2):258-266. Abstract
May 2013
Janes H, Gilbert P, Buchbinder S, Kublin J, Sobieszczyk ME, Hammer SM.  2013.  In Pursuit of an HIV Vaccine: Designing Efficacy Trials in the Context of Partially Effective Non-Vaccine Prevention Modalities.. AIDS research and human retroviruses. Abstract